Skip to main content Help with accessibility Skip to main navigation

February 2024 updates to the website

The website has now been updated following February's LSCMMG

The following guidelines have been added/updated:

Denosumab 120mg shared care - added

Denosumab 60mg shared care - updated

Atrial fibrillation guideline - update to follow pending amendments

Rimegepant position statement - added

Testosterone shared care - updated

Dosulepin guidance for primary care - added

Tirzepatide for type 2 diabetes position statement - to follow pending LSC ICB executive committee

Tirzepatide for weight loss position statement - to follow pending LSC ICB executive committee

The following medicines have been added/updated following the latest Clinical Effectiveness Group (CEG) / Commissioning Resource Group (CRG) meeting:

Morphine Sulfate Orodispersible Tablets (Actimorph®) - severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Anastrozole - Primary prevention of breast cancer in postmenopausal women at moderate or high risk

Ulipristal (Esmya) - for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed (RAG review)

Ibandronic acid injection - Treatment of post menopausal osteoporosis (RAG review)

Denosumab 120mg - Bone metastasis from solid tumours NICE TA265 (RAG review)

Empagliflozin - chronic heart failure with preserved or mildly reduced ejection fraction NICE TA929

Empagliflozin - chronic kidney disease NICE TA942

The following Items will be updated and added to the website following the next  Clinical Effectiveness Group (CEG) / Commissioning Resource Group (CRG) Meeting:

Hybrid closed-loop interim position statement - to follow pending amendments and ratification

Melatonin liquid (Ceyesto)